Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ziprasidone Effect on Metabolic Syndrome Risk Factors
NCT00748566Phase 4Terminated
- Sponsor
- Viatris
- Start
- Dec 2008
- Primary completion
- May 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of ziprasidone in schizophrenia and psychotic disorders, sponsored by Viatris. Primary endpoint: Percentage of Participants Achieving at Least 1 Risk Factor Reduction From Baseline for Metabolic Syndrome at Week 52. Started Dec 2008; status: terminated.
02
Drugs
ziprasidone
03
Conditions
schizophreniapsychotic disorders
Beyond the preview
Go deeper on NCT00748566.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00748566.